Expression of Interest call from CRUK Combinations Alliance

Dear all, CRUK Combinations Alliance are pleased to announce that a new agent from Astex Pharmaceuticals is on offer to […]

New data on NET prevalence and incidence in England

NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in […]

Prof Tim Meyer is new Chair of NCRI NET sub-group

It is a great honour to have been invited to take on the Chair of the NCRI NET sub-group. Under […]

Defining the Immune Landscape in Neuroendocrine Tumours

With the support of a one year pilot grant from NETRF, Tim Meyer established a collaborative group at UCL to […]

International team receive $1.2 million boost for NET research

A scientific collaboration between UCL, Dana-Farber Cancer Institute, UCSF Medical Centre and the UCL Cancer Institute / Royal Free Hospital […]

NET Genomics England Clinical Interpretation Partnership (GeCIP) subgroup

The UKINETs Research Committee are currently setting up a Neuroendocrine tumour domain of the Genomics England Clinical Interpretation Partnership (GeCIP). GeCIPs […]

Neuroendocrine tumour Genomics England Clinical Interpretation Partnership (GeCIP) domain

The UKINETs Research Committee are in the process of putting together an application to set up a Neuroendocrine tumour domain as […]

Bowel Cancer Screening Programme and NETs in England

This project was completed by Katy Odonnell , Ron Basuroy and John Ramage following a grant from NET Patient Foundation. […]

NPF seeks National Cancer Data Analyst

Please share this with your networks: National NET Patient Foundation Cancer Analyst Circa £30,000 pro rata (London) Circa £27,000 pro […]

NPF seeks data analyst to work on NET data project

The NET Patient Foundation is seeking an analyst to work part time with Public Health England on a project to […]

NET news from ESMO16

Update on the NET news from ESMO in Copenhagen – the biggest congress so far attended by over 20 500 […]

NET-02 study to open

NET-02:  A multi-centre, randomised, open-label, phase II trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line […]